FDA Scraps Biannual Biologics Inspections for Risk-Based Approach
The FDA is scrapping requirements that biologics be inspected at least every two years, moving instead to a risk-based schedule.
Source: Drug GMP Report
The FDA is scrapping requirements that biologics be inspected at least every two years, moving instead to a risk-based schedule.
Source: Drug GMP Report